<HTML>
<HEAD>
<TITLE>KING PHARMACEUTICALS, INC.</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>




<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="50%"></TD>
    <TD width="3%"></TD>
    <TD width="46%"></TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="left" valign="top">As filed with the Securities and
Exchange Commission on July 27, 2005.
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">Registration No.333-&#95;&#95;&#95;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<P align="center" style="font-size: 14pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B>

<DIV align="center" style="font-size: 12pt"><B>Washington, D.C. 20549</B>
</DIV>


<P align="center" style="font-size: 10pt"><DIV align="center"><DIV style="font-size: 3pt; margin-top: 16pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV></DIV>


<P align="center" style="font-size: 18pt"><B>FORM S-8</B>


<P align="center" style="font-size: 10pt"><DIV align="center"><DIV style="font-size: 3pt; margin-top: 16pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV></DIV>


<DIV align="center" style="font-size: 12pt"><B>REGISTRATION STATEMENT<BR>
UNDER<BR>
THE SECURITIES ACT OF 1933</B>
</DIV>

<P align="center" style="font-size: 24pt"><B>KING PHARMACEUTICALS, INC.</B>


<DIV align="center" style="font-size: 10pt">(Exact name of Registrant as specified in its charter)</DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="47%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>Tennessee</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>54-1684963</B></TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">(State or other jurisdiction of<BR>
incorporation or organization)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(I.R.S. Employer<BR>
Identification No.)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><B>501 Fifth Street<BR>
Bristol, Tennessee 37620</B><BR>
(Address of Principal Executive Offices including zip code)


<P align="center" style="font-size: 18pt"><B>KING PHARMACEUTICALS, INC. EXECUTIVE DEFERRED COMPENSATION PLAN</B>


<DIV align="center" style="font-size: 10pt">(Full title of the plan)</DIV>






<P align="center" style="font-size: 10pt"><B>Brian A. Markison<br>
President and Chief Executive Officer<br>
501 Fifth Street<BR>
Bristol, Tennessee 37620<BR>
(423)&nbsp;989-8000</B>


<DIV align="center" style="font-size: 10pt">(Name, address, including zip code, and telephone number, including area code, of agent for
service)</DIV>



<P align="center" style="font-size: 10pt"><I>Copy to</I>:



<P align="center" style="font-size: 10pt">Linda Crouch-McCreadie, Esq.<BR>
Baker, Donelson, Bearman, Caldwell &#038; Berkowitz, PC<BR>
207 Mockingbird Lane, Suite&nbsp;300<BR>
Johnson City, Tennessee 37604<BR>
(423)&nbsp;928-0181



<P align="center" style="font-size: 10pt"><B>CALCULATION OF REGISTRATION FEE</B>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="1%">&nbsp;</TD>
    <TD width="29%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD><!-- VRule -->
    <TD width="2%">&nbsp;</TD>
    <TD width="20%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD><!-- VRule -->
    <TD width="2%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD><!-- VRule -->
    <TD width="2%">&nbsp;</TD>
    <TD width="20%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD><!-- VRule -->
    <TD width="2%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>

    <TD width="1%">&nbsp;</TD>
</TR><TR style="font-size: 1px" valign="bottom">
    <TD nowrap align="left" colspan="15" style="border-bottom: 3px solid #000000">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">    <TD width="1%">&nbsp;</TD>

    <TD>&nbsp;</TD>
    <TD style="border-right: 2px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD style="border-right: 2px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>Proposed maximum</B></TD>
    <TD style="border-right: 2px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>Proposed maximum</B></TD>
    <TD style="border-right: 2px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">    <TD width="1%">&nbsp;</TD>

    <TD nowrap align="center"><B>Title of securities</B></TD>
    <TD style="border-right: 2px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>Amount to be</B></TD>
    <TD style="border-right: 2px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>offering price</B></TD>
    <TD style="border-right: 2px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>aggregate offering</B></TD>
    <TD style="border-right: 2px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>Amount of</B></TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">    <TD width="1%">&nbsp;</TD>

    <TD nowrap align="center"><B>to be registered</B></TD>
    <TD style="border-right: 2px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>registered</B></TD>
    <TD style="border-right: 2px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>per obligation</B></TD>
    <TD style="border-right: 2px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>price </B><SUP style="font-size: 85%; vertical-align: text-top"><B>(2)</B></SUP></TD>
    <TD style="border-right: 2px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>registration fee</B></TD>
    <TD width="1%">&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD width="1%" style="border-top: 2px solid #000000">&nbsp;</TD>
                    <TD style="border-top: 2px solid #000000"><DIV style="margin-left:15px; text-indent:-15px">Deferred
Compensation
Obligations
<SUP style="font-size: 85%; vertical-align: text-top"><B>(1)</B></SUP></DIV></TD>
    <TD style="border-right: 2px solid #000000; border-top: 2px solid #000000">&nbsp;</TD>
    <TD style="border-top: 2px solid #000000">&nbsp;</TD>
    <TD align="center" valign="bottom" style="border-top: 2px solid #000000">$20,000,000</TD>
    <TD style="border-right: 2px solid #000000; border-top: 2px solid #000000">&nbsp;</TD>
    <TD style="border-top: 2px solid #000000">&nbsp;</TD>
    <TD align="center" valign="bottom" style="border-top: 2px solid #000000">100%</TD>
    <TD style="border-right: 2px solid #000000; border-top: 2px solid #000000">&nbsp;</TD>
    <TD style="border-top: 2px solid #000000">&nbsp;</TD>
    <TD align="center" valign="bottom" style="border-top: 2px solid #000000">$20,000,000</TD>
    <TD style="border-right: 2px solid #000000; border-top: 2px solid #000000">&nbsp;</TD>
    <TD style="border-top: 2px solid #000000">&nbsp;</TD>
    <TD align="center" valign="bottom" style="border-top: 2px solid #000000">$2,354</TD>
    <TD width="1%" style="border-top: 2px solid #000000">&nbsp;</TD>
</TR>
<TR style="font-size: 1px" valign="bottom">
    <TD nowrap align="left" colspan="15" style="border-top: 3px solid #000000">&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>

<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">(1)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Deferred Compensation Obligations are unsecured obligations of King Pharmaceuticals, Inc.
to pay deferred compensation in the future in accordance with the terms of the 2005 King
Pharmaceuticals, Inc. Executive Deferred Compensation Plan.</TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">(2)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Estimated solely for the purposes of determining the registration fee.</TD>
</TR>

</TABLE>


<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>





<P align="center" style="font-size: 10pt">1
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<!-- TOC -->
<A name="toc"><DIV align="CENTER" style="page-break-before:always"><U><B>TABLE OF CONTENTS</B></U></DIV></A>

<P><CENTER>
<TABLE border="0" width="90%" cellpadding="0" cellspacing="0">
<TR>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="76%"></TD>
</TR>
<TR><TD colspan="9"><A HREF="#000">PART I INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS</A></TD></TR>
<TR><TD colspan="9"><A HREF="#001">PART II INFORMATION REQUIRED IN THE REGISTRATION STATEMENT</A></TD></TR>
<TR><TD></TD><TD colspan="8"><A HREF="#002">Item&nbsp;3. Incorporation of Documents By Reference.</A></TD></TR>
<TR><TD></TD><TD colspan="8"><A HREF="#003">Item&nbsp;4. Description of Securities.</A></TD></TR>
<TR><TD></TD><TD colspan="8"><A HREF="#004">Item&nbsp;5. Interests of Named Experts and Counsel.</A></TD></TR>
<TR><TD></TD><TD colspan="8"><A HREF="#005">Item&nbsp;6. Indemnification of Directors and Officers.</A></TD></TR>
<TR><TD></TD><TD colspan="8"><A HREF="#006">Item&nbsp;7. Exemption from Registration Claimed.</A></TD></TR>
<TR><TD></TD><TD colspan="8"><A HREF="#007">Item&nbsp;8. Exhibits.</A></TD></TR>
<TR><TD></TD><TD colspan="8"><A HREF="#008">Item&nbsp;9. Undertakings.</A></TD></TR>
<TR><TD colspan="9"><A HREF="#009">SIGNATURES</A></TD></TR>
<TR><TD colspan="9"><A HREF="g96410exv4w3.txt">EX-4.3  EXECUTIVE DEFERRED COMPENSATION PLAN</A></TD></TR>
<TR><TD colspan="9"><A HREF="g96410exv5w1.txt">EX-5.1  OPINION OF BAKER, DONELSON, BEARMAN, CALDWELL & BERKOWITZ, PC</A></TD></TR>
<TR><TD colspan="9"><A HREF="g96410exv10.txt">EX-10  TRUST UNDER THE KING PHARMACEUTICALS, INC. EXECUTIVE DEFERRED COMPENSATION PLAN</A></TD></TR>
<TR><TD colspan="9"><A HREF="g96410exv23w1.txt">EX-23.1  CONSENT OF PRICEWATERHOUSECOOPERS, LLP</A></TD></TR>
</TABLE>
</CENTER>
<!-- /TOC -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>




<!-- link1 "PART I INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS" -->
<DIV align="left"><A NAME="000"></A></DIV>

<P align="center" style="font-size: 10pt"><B>PART I</B>



<P align="center" style="font-size: 10pt"><B>INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS</B>



<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The documents containing the information specified in Part&nbsp;I of this Registration Statement on
Form S-8 will be sent or given to the participant in the plan as specified under Rule&nbsp;428(b)(1)
under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;). Such documents are not
required to be, and are not being, filed by King Pharmaceuticals, Inc. (the &#147;Company&#148;) with the
Securities and Exchange Commission (the &#147;Commission&#148;), either as part of this Registration
Statement or as prospectuses or prospectus supplements pursuant to Rule&nbsp;424 under the Securities
Act. Such documents, together with the documents incorporated by reference herein pursuant to Item
3 of Part&nbsp;II of this Registration Statement on Form S-8, constitute a prospectus that meets the
requirements of Section 10(a) of the Securities Act.

<!-- link1 "PART II INFORMATION REQUIRED IN THE REGISTRATION STATEMENT" -->
<DIV align="left"><A NAME="001"></A></DIV>

<P align="center" style="font-size: 10pt"><B>PART II</B>



<P align="center" style="font-size: 10pt"><B>INFORMATION REQUIRED IN THE REGISTRATION STATEMENT</B>


<!-- link2 "Item&nbsp;3. Incorporation of Documents By Reference." -->
<DIV align="left"><A NAME="002"></A></DIV>

<P align="left" style="font-size: 10pt"><B>Item&nbsp;3. Incorporation of Documents By Reference.</B>



<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company has filed the following document(s) with the Commission and incorporates them
herein by reference:


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Company&#146;s Annual Report on Form 10-K for the year ended
December&nbsp;31, 2004, filed with the Commission on March&nbsp;21, 2005.</TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Company&#146;s Quarterly Report on Form 10-Q for the quarter ended
March&nbsp;31, 2005, filed with the Commission on May&nbsp;10 2005.</TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The Company&#146;s Current Reports on Form 8-K filed February&nbsp;22, March
1, March&nbsp;17, March&nbsp;21, April&nbsp;12, May&nbsp;3, May&nbsp;9, May&nbsp;27, and June&nbsp;6, 2005.</TD>
</TR>

</TABLE>


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All reports and other documents subsequently filed by the Company pursuant to Sections&nbsp;13(a),
13(c), 14 and 15(d) of the Exchange Act prior to the filing of a post-effective amendment
indicating that all securities offered hereby have been sold or deregistering all securities then
remaining unsold shall be deemed to be incorporated herein by reference and to be a part hereof
from the date of the filing of such reports and documents.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any statement contained in a document incorporated or deemed to be incorporated by reference
herein shall be deemed to be modified or superseded for purposes of this Registration Statement to
the extent that a statement contained herein or in any other subsequently filed document which also
is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any
statement so modified or superseded shall not be deemed, except as so modified or superseded, to
constitute a part of this Registration Statement.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company will provide, without charge, to each plan participant a copy of the documents
incorporated by reference in Item&nbsp;3 of Part&nbsp;II of this registration statement, upon written or oral
request. Further, we will provide plan participants, without charge, upon written or oral request,
other documents required to be delivered pursuant to Commission Rule&nbsp;428(b). Written requests
should be directed to King Pharmaceuticals, Inc., Attn: Taft Simmons, 501 Fifth Street, Bristol,
Tennessee, 37620. Telephone requests may be directed to Taft Simmons at
(423)&nbsp;989-8000.

<!-- link2 "Item&nbsp;4. Description of Securities." -->
<DIV align="left"><A NAME="003"></A></DIV>

<P align="left" style="font-size: 10pt"><B>Item&nbsp;4. Description of Securities.</B>



<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If eligible employees elect to participate in the Plan, their deferrals of compensation
pursuant to the Plan will represent purchases of securities known as &#147;Deferred Compensation
Obligations&#148; (the &#147;Obligations&#148;) of the Company. The Obligations are securities and are
considered unsecured general contractual obligations of the Company that rank <U><I>pari passu</I></U>
with other unsecured and unsubordinated indebtedness of the Company. The Obligations are
contractual promises by the Company to distribute to Participants in the Plan, upon their
retirement,


<P align="center" style="font-size: 10pt">2
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<P align="left" style="font-size: 10pt">termination of employment and/or at certain other times specified in the Plan, compensation
deferred under the Plan, Company Discretionary Contributions (if any), and investment returns,
positive or negative, thereon that are credited to the account(s) in accordance with the terms of
the Plan. The Obligations are payable in cash either in a lump-sum distribution or in
installments, in accordance with the terms of the Plan. The Plan may be amended, modified or
terminated at any time, provided that such amendment, modification or termination may not adversely
affect benefits already accrued without the consent of the affected Participants. There is no
trading market for the Obligations. Pursuant to the Plan, the Company will offer an indeterminate
amount of its Deferred Compensation Obligations to Eligible Employees.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Obligations are not, prior to payment, subject in any manner, either voluntarily or
involuntarily, to anticipation, alienation, sale, transfer, assignment, pledge, encumbrance,
attachment or garnishment. Any attempt by any person to transfer or assign benefits under the
Plan, other than a claim for benefits by a Participant or his or her beneficiary(ies), will be
null, void and of no effect.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Obligations are not convertible into any other security of the Company. No trustee has
been appointed to take action with respect to the Obligations, and each Participant in the Plan
will be responsible for enforcing his or her own rights with respect to the Obligations.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Participants in the Plan will have no rights to any assets held by a rabbi trust, including
that certain Trust Under the King Pharmaceuticals, Inc. Executive Deferred Compensation Plan.,
except as general creditors of the Company. Assets of any rabbi trust will be subject to the
claims of the Company&#146;s and participation subsidiary(ies)&#146; and/or affiliates&#146; general creditors in
the event of the Company&#146;s or participating subsidiary&#146;s or affiliate&#146;s insolvency.

<!-- link2 "Item&nbsp;5. Interests of Named Experts and Counsel." -->
<DIV align="left"><A NAME="004"></A></DIV>

<P align="left" style="font-size: 10pt"><B>Item&nbsp;5. Interests of Named Experts and Counsel.</B>



<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Not applicable.

<!-- link2 "Item&nbsp;6. Indemnification of Directors and Officers." -->
<DIV align="left"><A NAME="005"></A></DIV>

<P align="left" style="font-size: 10pt"><B>Item&nbsp;6. Indemnification of Directors and Officers.</B>



<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Tennessee Business Corporation Act (the &#147;Act&#148;) provides financial protection by the
Company for its directors, officers and employees against liabilities and expenses (including
attorneys&#146; fees, judgments, fines, ERISA excise taxes or penalties and amounts paid in settlement)
incurred by them in proceedings arising out of their position with the Company.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under the Act&#146;s permissive indemnification provisions, a corporation has the authority to
indemnify a director against liability incurred in a proceeding if the director conducted himself
in good faith and in a manner he reasonably believed to be in the corporation&#146;s best interests. In
the case of criminal proceedings, the director must have no reasonable cause to believe his conduct
was unlawful. Permissive indemnification is allowed even if the director is not wholly successful
in the proceeding. Indemnification is, however, prohibited in derivative actions in which the
director is adjudged liable and in situations in which the director is found liable on the basis
that a personal benefit was improperly received by him. The Act also provides that unless limited
by its charter, a corporation must indemnify a director who is wholly successful on the merits or
otherwise in the defense of a proceeding against reasonable expenses incurred in connection with
the proceeding. In addition to providing indemnification for liabilities for which the director is
held liable, the Act also provides that a corporation may advance expenses incurred by a director
if the director can furnish a written statement of his good faith belief that he acted in an
appropriate manner and undertakes to repay the amount advanced if it is ultimately determined that
he was not entitled to indemnification.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Act contains provisions extending indemnification to officers, employees and agents of the
corporation. The Act states that a corporation may also indemnify and advance expenses to an
officer, employee or agent who is not a director to the extent consistent with public policy, that
may be provided by its charter, bylaws, general or specific action of its board of directors or
contract.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company&#146;s Charter and Bylaws provide for indemnification of directors, officers, employees
and agents to the fullest extent allowed for by Tennessee law.


<P align="center" style="font-size: 10pt">3
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company also maintains liability insurance for directors and officers, as authorized by the Act.

<!-- link2 "Item&nbsp;7. Exemption from Registration Claimed." -->
<DIV align="left"><A NAME="006"></A></DIV>

<P align="left" style="font-size: 10pt"><B>Item&nbsp;7. Exemption from Registration Claimed.</B>



<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Not applicable.

<!-- link2 "Item&nbsp;8. Exhibits." -->
<DIV align="left"><A NAME="007"></A></DIV>

<P align="left" style="font-size: 10pt"><B>Item&nbsp;8. Exhibits.</B>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="90%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000">Exhibit No.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" style="border-bottom: 1px solid #000000">Description</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">4.1</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Second Amended and Restated Charter of King Pharmaceuticals, Inc (previously
filed as Exhibit&nbsp;3.1(a) to the Company&#146;s Registration Statement No.&nbsp;333-38753 on Form
S-1 filed with the Commission on October&nbsp;24, 1997, and incorporated by reference).</DIV></TD>
</TR>
<TR valign="bottom">
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">4.2</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Amended and Restated Bylaws of King Pharmaceuticals, Inc (previously filed as
Exhibit&nbsp;3.2(a) to the Company&#146;s Registration Statement No.&nbsp;333-38753 on Form&nbsp;S-1 filed
with the Commission on October&nbsp;24, 1997, and incorporated by reference).</DIV></TD>
</TR>
<TR valign="bottom">
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">4.3</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">King Pharmaceuticals, Inc. Executive Deferred Compensation Plan.</DIV></TD>
</TR>
<TR valign="bottom">
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">5.1</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Opinion of Baker, Donelson, Bearman. Caldwell &#038; Berkowitz, PC as to the
legality of the shares being registered.</DIV></TD>
</TR>
<TR valign="bottom">
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="left" valign="top">10</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Trust Under the King Pharmaceuticals, Inc. Executive Deferred Compensation
Plan.</DIV></TD>
</TR>
<TR valign="bottom">
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">23.1</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Consent of PricewaterhouseCoopers, LLP.</DIV></TD>
</TR>
<TR valign="bottom">
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">23.2</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Consent of Baker, Donelson, Bearman, Caldwell &#038; Berkowitz, PC (included in
Exhibit&nbsp;5.1 to the Registration Statement.) (1).</DIV></TD>
</TR>
<TR valign="bottom">
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">24.1</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Power of Attorney (included in the signatures to the Registration Statement).</DIV></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<DIV align="left">
<DIV style="font-size: 3pt; margin-top: 16pt; width: 18%; border-top: 1px solid #000000">&nbsp;</DIV>
</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top">
    <TD width="3%" nowrap align="left">(1)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="96%">The Plan is intended to be an unfunded arrangement providing deferred compensation to
eligible employees who are part of a select group of management or highly compensated
employees of King, including subsidiaries and affiliates to the extent permitted by King,
within the meaning of Sections&nbsp;201, 301 and 401 of ERISA. A
&#147;top-hat&#148; plan exemption will be filed with the Department of Labor to exempt the Plan from the requirements of Parts 2,
3 and 4 of Title I of ERISA as a &#147;top hat&#148; plan, and to be eligible for the alternative
method of compliance for reporting and disclosure available for unfunded &#147;top hat&#148; plans.
Thus, no formal legal opinion regarding the Plan&#146;s compliance with the specific plan term
requirements of Parts 2, 3 and 4 is applicable or required.</TD>
</TR>

</TABLE>


<!-- link2 "Item&nbsp;9. Undertakings." -->
<DIV align="left"><A NAME="008"></A></DIV>

<P align="left" style="font-size: 10pt"><B>Item&nbsp;9. Undertakings.</B>



<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;The undersigned Registrant hereby undertakes:



<P align="left" style="margin-left:3%; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) To file, during any period in which offers or sales are being made, a post-effective
amendment to the Registration Statement:



<P align="left" style="margin-left:6%; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) To include any prospectus required by Section&nbsp;10(a)(3) of the Securities Act of
1933 (the &#147;Securities Act&#148;);



<P align="left" style="margin-left:6%; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) To reflect in the prospectus any facts or events arising after the effective
date of this registration statement (or the most recent post-effective amendment thereof)
which, individually or in the aggregate, represent a fundamental change in the information
set forth in this registration statement. Notwithstanding the foregoing, any increase or
decrease in volume of securities offered (if the total


<P align="center" style="font-size: 10pt">4
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<P align="left" style="margin-left:6%; font-size: 10pt">dollar value of the securities offered would not exceed what was registered) and any
deviation from the low or high end of the estimated maximum offering range may be
reflected in the form of a prospectus filed with the Commission pursuant to Rule 424(b)
if, in the aggregate, the changes in volume and price represent no more than a 20&nbsp;percent
change in the maximum aggregate offering price set forth in the &#147;Calculation of
Registration Fee&#148; table in the effective registration statement;



<P align="left" style="margin-left:6%; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) To include any material information with respect to the plan of distribution
not previously disclosed in this registration statement or any material change to such
information in this registration statement;



<P align="left" style="margin-left:3%; font-size: 10pt"><U>provided</U>, <U>however</U>, that sections (a)(1)(i) and (a)(1)(ii) do not apply if the
information required to be included in a post-effective amendment by those paragraphs is
contained in periodic reports filed with or furnished to the Commission by the Registrant
pursuant to Section&nbsp;13 or Section 15(d) of the Securities Exchange Act of 1934 (the &#147;Exchange
Act&#148;) that are incorporated by reference in this registration statement;



<P align="left" style="margin-left:3%; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) That, for the purpose of determining any liability under the Securities Act, each such
post-effective amendment shall be deemed to be a new registration statement relating to the
securities offered therein, and the offering of such securities at that time shall be deemed to
be the initial bona fide offering thereof; and



<P align="left" style="margin-left:3%; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3) To remove from registration by means of a post-effective amendment any of the
securities being registered which remain unsold at the termination of this offering.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;The undersigned Registrant hereby undertakes that, for purposes of determining any liability
under the Securities Act, each filing of the Registrant&#146;s annual report pursuant to Section 13(a)
or Section 15(d) of the Exchange Act that is incorporated by reference in this registration
statement shall be deemed to be a new registration statement relating to the securities offered
therein, and the offering of such securities at that time shall be deemed to be the initial bona
fide offering thereof.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Insofar as indemnification for liabilities arising under the Securities Act may be permitted to
directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions,
or otherwise, the Registrant has been advised that in the opinion of the Commission such
indemnification is against public policy as expressed in the Act and is, therefore, unenforceable.
In the event that a claim for indemnification against such liabilities (other than the payment by
the Registrant of expenses incurred or paid by a director, officer or controlling person of the
Registrant in the successful defense of any action, suit, or proceeding) is asserted by such
director, officer or controlling person in connection with the securities being registered, the
Registrant will, unless in the opinion of its counsel the matter has been settled by controlling
precedent, submit to a court of appropriate jurisdiction the question whether such indemnification
by it is against public policy as expressed in the Act and will be governed by the final
adjudication of such issue.



<P align="center" style="font-size: 10pt">5
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<!-- link1 "SIGNATURES" -->
<DIV align="left"><A NAME="009"></A></DIV>

<P align="center" style="font-size: 10pt"><B>SIGNATURES</B>



<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it
has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and
has duly caused this registration statement to be signed on its behalf by the undersigned,
thereunto duly authorized, in the City of Bristol, State of
Tennessee, on this 22nd day of July&nbsp;2005.


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">KING PHARMACEUTICALS, INC.<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Brian A. Markison
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Brian A. Markison&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">President and Chief Executive Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<P align="center" style="font-size: 10pt"><B>POWER OF ATTORNEY</B>




<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;KNOW ALL MEN BY THESE PRESENTS that the undersigned officers and directors of King
Pharmaceuticals, Inc., a Tennessee corporation, hereby constitute and appoint Brian A. Markison the
true and lawful agent and attorney-in-fact, with all power of substitution and resubstitution, to
sign for the undersigned, in their respective names as officers and directors of the corporation,
one or more registration statements on Form S-8 (or other appropriate form) to be filed with the
Securities and Exchange Commission, Washington, D.C., under the Securities Act of 1933, as amended,
and any amendment or supplement to such registration statement, relating to the King
Pharmaceuticals, Inc. Executive Deferred Compensation Plan; hereby ratifying and confirming all
acts taken by such agent and attorney-in-fact as herein authorized.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Act of 1933, as amended, this registration
statement has been signed by the following persons in the capacities
indicated and as of July 22, 2005.

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="48%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="46%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="22%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="23%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000">Signature</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000">Title</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ Brian A. Markison
<HR size="1" noshade color="#000000">
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">President, Chief Executive Officer and Director&nbsp;(principal
executive officer)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Brian A. Markison</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ Joseph Squicciarino
<HR size="1" noshade color="#000000">
Joseph Squicciarino
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Chief Financial Officer<BR>
(principal financial officer)</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ Ted G. Wood
<HR size="1" noshade color="#000000">
Ted G. Wood
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Chairman of the Board, Director</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ Earnest W. Deavenport, Jr.
<HR size="1" noshade color="#000000">
Earnest W. Deavenport, Jr.
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Director</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ Elizabeth M. Greetham
<HR size="1" noshade color="#000000">
Elizabeth M. Greetham
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Director</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ Gregory D. Jordan
<HR size="1" noshade color="#000000">
Gregory D. Jordan
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Director</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ R. Charles Moyer
<HR size="1" noshade color="#000000">
R. Charles Moyer
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Director</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt">6
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="48%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="46%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="22%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="23%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000">Signature</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000">Title</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ Philip M. Pfeffer
<HR size="1" noshade color="#000000">
Philip M. Pfeffer
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Director</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ D. Greg Rooker
<HR size="1" noshade color="#000000">
D. Greg Rooker
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Director</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt">7
</DIV>


</BODY>
</HTML>
[{"type": "S-8", "sequence": "1", "filename": "g96410sv8.htm", "description": "KING PHARMACEUTICALS, INC.", "secsgml_size_bytes": 43557}]
{"company-data": {"conformed-name": "KING PHARMACEUTICALS INC", "cik": "0001047699", "assigned-sic": "2834", "irs-number": "541684963", "state-of-incorporation": "TN", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "S-8", "act": "33", "file-number": "333-126939", "film-number": "05978270"}, "business-address": {"street1": "501 FIFTH ST", "city": "BRISTOL", "state": "TN", "zip": "37620", "phone": "4239898000"}, "mail-address": {"street1": "501 FIFTH ST", "city": "BRISTOL", "state": "TN", "zip": "37620"}}
KING PHARMACEUTICALS, INC.
Table of Contents
As filed with the Securities and
Exchange Commission on July 27, 2005.
Registration No.333-___
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
KING PHARMACEUTICALS, INC.
(Exact name of Registrant as specified in its charter)
Tennessee
54-1684963
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification No.)
501 Fifth Street
Bristol, Tennessee 37620
(Address of Principal Executive Offices including zip code)
KING PHARMACEUTICALS, INC. EXECUTIVE DEFERRED COMPENSATION PLAN
(Full title of the plan)
Brian A. Markison
President and Chief Executive Officer
501 Fifth Street
Bristol, Tennessee 37620
(423) 989-8000
(Name, address, including zip code, and telephone number, including area code, of agent for
service)
Copy to
:
Linda Crouch-McCreadie, Esq.
Baker, Donelson, Bearman, Caldwell & Berkowitz, PC
207 Mockingbird Lane, Suite 300
Johnson City, Tennessee 37604
(423) 928-0181
CALCULATION OF REGISTRATION FEE
Proposed maximum
Proposed maximum
Title of securities
Amount to be
offering price
aggregate offering
Amount of
to be registered
registered
per obligation
price
(2)
registration fee
Deferred
Compensation
Obligations
(1)
$20,000,000
100%
$20,000,000
$2,354
(1)
The Deferred Compensation Obligations are unsecured obligations of King Pharmaceuticals, Inc.
to pay deferred compensation in the future in accordance with the terms of the 2005 King
Pharmaceuticals, Inc. Executive Deferred Compensation Plan.
(2)
Estimated solely for the purposes of determining the registration fee.
1
TABLE OF CONTENTS
PART I INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
PART II INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 3. Incorporation of Documents By Reference.
Item 4. Description of Securities.
Item 5. Interests of Named Experts and Counsel.
Item 6. Indemnification of Directors and Officers.
Item 7. Exemption from Registration Claimed.
Item 8. Exhibits.
Item 9. Undertakings.
SIGNATURES
EX-4.3  EXECUTIVE DEFERRED COMPENSATION PLAN
EX-5.1  OPINION OF BAKER, DONELSON, BEARMAN, CALDWELL & BERKOWITZ, PC
EX-10  TRUST UNDER THE KING PHARMACEUTICALS, INC. EXECUTIVE DEFERRED COMPENSATION PLAN
EX-23.1  CONSENT OF PRICEWATERHOUSECOOPERS, LLP
Table of Contents
PART I
INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
The documents containing the information specified in Part I of this Registration Statement on
Form S-8 will be sent or given to the participant in the plan as specified under Rule 428(b)(1)
under the Securities Act of 1933, as amended (the "Securities Act"). Such documents are not
required to be, and are not being, filed by King Pharmaceuticals, Inc. (the "Company") with the
Securities and Exchange Commission (the "Commission"), either as part of this Registration
Statement or as prospectuses or prospectus supplements pursuant to Rule 424 under the Securities
Act. Such documents, together with the documents incorporated by reference herein pursuant to Item
3 of Part II of this Registration Statement on Form S-8, constitute a prospectus that meets the
requirements of Section 10(a) of the Securities Act.
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 3. Incorporation of Documents By Reference.
The Company has filed the following document(s) with the Commission and incorporates them
herein by reference:
1.
The Company's Annual Report on Form 10-K for the year ended
December 31, 2004, filed with the Commission on March 21, 2005.
2.
The Company's Quarterly Report on Form 10-Q for the quarter ended
March 31, 2005, filed with the Commission on May 10 2005.
3.
The Company's Current Reports on Form 8-K filed February 22, March
1, March 17, March 21, April 12, May 3, May 9, May 27, and June 6, 2005.
All reports and other documents subsequently filed by the Company pursuant to Sections 13(a),
13(c), 14 and 15(d) of the Exchange Act prior to the filing of a post-effective amendment
indicating that all securities offered hereby have been sold or deregistering all securities then
remaining unsold shall be deemed to be incorporated herein by reference and to be a part hereof
from the date of the filing of such reports and documents.
Any statement contained in a document incorporated or deemed to be incorporated by reference
herein shall be deemed to be modified or superseded for purposes of this Registration Statement to
the extent that a statement contained herein or in any other subsequently filed document which also
is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any
statement so modified or superseded shall not be deemed, except as so modified or superseded, to
constitute a part of this Registration Statement.
The Company will provide, without charge, to each plan participant a copy of the documents
incorporated by reference in Item 3 of Part II of this registration statement, upon written or oral
request. Further, we will provide plan participants, without charge, upon written or oral request,
other documents required to be delivered pursuant to Commission Rule 428(b). Written requests
should be directed to King Pharmaceuticals, Inc., Attn: Taft Simmons, 501 Fifth Street, Bristol,
Tennessee, 37620. Telephone requests may be directed to Taft Simmons at
(423) 989-8000.
Item 4. Description of Securities.
If eligible employees elect to participate in the Plan, their deferrals of compensation
pursuant to the Plan will represent purchases of securities known as "Deferred Compensation
Obligations" (the "Obligations") of the Company. The Obligations are securities and are
considered unsecured general contractual obligations of the Company that rank
pari passu
with other unsecured and unsubordinated indebtedness of the Company. The Obligations are
contractual promises by the Company to distribute to Participants in the Plan, upon their
retirement,
2
Table of Contents
termination of employment and/or at certain other times specified in the Plan, compensation
deferred under the Plan, Company Discretionary Contributions (if any), and investment returns,
positive or negative, thereon that are credited to the account(s) in accordance with the terms of
the Plan. The Obligations are payable in cash either in a lump-sum distribution or in
installments, in accordance with the terms of the Plan. The Plan may be amended, modified or
terminated at any time, provided that such amendment, modification or termination may not adversely
affect benefits already accrued without the consent of the affected Participants. There is no
trading market for the Obligations. Pursuant to the Plan, the Company will offer an indeterminate
amount of its Deferred Compensation Obligations to Eligible Employees.
The Obligations are not, prior to payment, subject in any manner, either voluntarily or
involuntarily, to anticipation, alienation, sale, transfer, assignment, pledge, encumbrance,
attachment or garnishment. Any attempt by any person to transfer or assign benefits under the
Plan, other than a claim for benefits by a Participant or his or her beneficiary(ies), will be
null, void and of no effect.
The Obligations are not convertible into any other security of the Company. No trustee has
been appointed to take action with respect to the Obligations, and each Participant in the Plan
will be responsible for enforcing his or her own rights with respect to the Obligations.
Participants in the Plan will have no rights to any assets held by a rabbi trust, including
that certain Trust Under the King Pharmaceuticals, Inc. Executive Deferred Compensation Plan.,
except as general creditors of the Company. Assets of any rabbi trust will be subject to the
claims of the Company's and participation subsidiary(ies)' and/or affiliates' general creditors in
the event of the Company's or participating subsidiary's or affiliate's insolvency.
Item 5. Interests of Named Experts and Counsel.
Not applicable.
Item 6. Indemnification of Directors and Officers.
The Tennessee Business Corporation Act (the "Act") provides financial protection by the
Company for its directors, officers and employees against liabilities and expenses (including
attorneys' fees, judgments, fines, ERISA excise taxes or penalties and amounts paid in settlement)
incurred by them in proceedings arising out of their position with the Company.
Under the Act's permissive indemnification provisions, a corporation has the authority to
indemnify a director against liability incurred in a proceeding if the director conducted himself
in good faith and in a manner he reasonably believed to be in the corporation's best interests. In
the case of criminal proceedings, the director must have no reasonable cause to believe his conduct
was unlawful. Permissive indemnification is allowed even if the director is not wholly successful
in the proceeding. Indemnification is, however, prohibited in derivative actions in which the
director is adjudged liable and in situations in which the director is found liable on the basis
that a personal benefit was improperly received by him. The Act also provides that unless limited
by its charter, a corporation must indemnify a director who is wholly successful on the merits or
otherwise in the defense of a proceeding against reasonable expenses incurred in connection with
the proceeding. In addition to providing indemnification for liabilities for which the director is
held liable, the Act also provides that a corporation may advance expenses incurred by a director
if the director can furnish a written statement of his good faith belief that he acted in an
appropriate manner and undertakes to repay the amount advanced if it is ultimately determined that
he was not entitled to indemnification.
The Act contains provisions extending indemnification to officers, employees and agents of the
corporation. The Act states that a corporation may also indemnify and advance expenses to an
officer, employee or agent who is not a director to the extent consistent with public policy, that
may be provided by its charter, bylaws, general or specific action of its board of directors or
contract.
The Company's Charter and Bylaws provide for indemnification of directors, officers, employees
and agents to the fullest extent allowed for by Tennessee law.
3
Table of Contents
The Company also maintains liability insurance for directors and officers, as authorized by the Act.
Item 7. Exemption from Registration Claimed.
Not applicable.
Item 8. Exhibits.
Exhibit No.
Description
4.1
Second Amended and Restated Charter of King Pharmaceuticals, Inc (previously
filed as Exhibit 3.1(a) to the Company's Registration Statement No. 333-38753 on Form
S-1 filed with the Commission on October 24, 1997, and incorporated by reference).
4.2
Amended and Restated Bylaws of King Pharmaceuticals, Inc (previously filed as
Exhibit 3.2(a) to the Company's Registration Statement No. 333-38753 on Form S-1 filed
with the Commission on October 24, 1997, and incorporated by reference).
4.3
King Pharmaceuticals, Inc. Executive Deferred Compensation Plan.
5.1
Opinion of Baker, Donelson, Bearman. Caldwell & Berkowitz, PC as to the
legality of the shares being registered.
10
Trust Under the King Pharmaceuticals, Inc. Executive Deferred Compensation
Plan.
23.1
Consent of PricewaterhouseCoopers, LLP.
23.2
Consent of Baker, Donelson, Bearman, Caldwell & Berkowitz, PC (included in
Exhibit 5.1 to the Registration Statement.) (1).
24.1
Power of Attorney (included in the signatures to the Registration Statement).
(1)
The Plan is intended to be an unfunded arrangement providing deferred compensation to
eligible employees who are part of a select group of management or highly compensated
employees of King, including subsidiaries and affiliates to the extent permitted by King,
within the meaning of Sections 201, 301 and 401 of ERISA. A
"top-hat" plan exemption will be filed with the Department of Labor to exempt the Plan from the requirements of Parts 2,
3 and 4 of Title I of ERISA as a "top hat" plan, and to be eligible for the alternative
method of compliance for reporting and disclosure available for unfunded "top hat" plans.
Thus, no formal legal opinion regarding the Plan's compliance with the specific plan term
requirements of Parts 2, 3 and 4 is applicable or required.
Item 9. Undertakings.
(a) The undersigned Registrant hereby undertakes:
(1) To file, during any period in which offers or sales are being made, a post-effective
amendment to the Registration Statement:
(i) To include any prospectus required by Section 10(a)(3) of the Securities Act of
1933 (the "Securities Act");
(ii) To reflect in the prospectus any facts or events arising after the effective
date of this registration statement (or the most recent post-effective amendment thereof)
which, individually or in the aggregate, represent a fundamental change in the information
set forth in this registration statement. Notwithstanding the foregoing, any increase or
decrease in volume of securities offered (if the total
4
Table of Contents
dollar value of the securities offered would not exceed what was registered) and any
deviation from the low or high end of the estimated maximum offering range may be
reflected in the form of a prospectus filed with the Commission pursuant to Rule 424(b)
if, in the aggregate, the changes in volume and price represent no more than a 20 percent
change in the maximum aggregate offering price set forth in the "Calculation of
Registration Fee" table in the effective registration statement;
(iii) To include any material information with respect to the plan of distribution
not previously disclosed in this registration statement or any material change to such
information in this registration statement;
provided
,
however
, that sections (a)(1)(i) and (a)(1)(ii) do not apply if the
information required to be included in a post-effective amendment by those paragraphs is
contained in periodic reports filed with or furnished to the Commission by the Registrant
pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 (the "Exchange
Act") that are incorporated by reference in this registration statement;
(2) That, for the purpose of determining any liability under the Securities Act, each such
post-effective amendment shall be deemed to be a new registration statement relating to the
securities offered therein, and the offering of such securities at that time shall be deemed to
be the initial bona fide offering thereof; and
(3) To remove from registration by means of a post-effective amendment any of the
securities being registered which remain unsold at the termination of this offering.
(b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability
under the Securities Act, each filing of the Registrant's annual report pursuant to Section 13(a)
or Section 15(d) of the Exchange Act that is incorporated by reference in this registration
statement shall be deemed to be a new registration statement relating to the securities offered
therein, and the offering of such securities at that time shall be deemed to be the initial bona
fide offering thereof.
(c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to
directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions,
or otherwise, the Registrant has been advised that in the opinion of the Commission such
indemnification is against public policy as expressed in the Act and is, therefore, unenforceable.
In the event that a claim for indemnification against such liabilities (other than the payment by
the Registrant of expenses incurred or paid by a director, officer or controlling person of the
Registrant in the successful defense of any action, suit, or proceeding) is asserted by such
director, officer or controlling person in connection with the securities being registered, the
Registrant will, unless in the opinion of its counsel the matter has been settled by controlling
precedent, submit to a court of appropriate jurisdiction the question whether such indemnification
by it is against public policy as expressed in the Act and will be governed by the final
adjudication of such issue.
5
Table of Contents
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it
has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and
has duly caused this registration statement to be signed on its behalf by the undersigned,
thereunto duly authorized, in the City of Bristol, State of
Tennessee, on this 22nd day of July 2005.
KING PHARMACEUTICALS, INC.
By:
/s/ Brian A. Markison
Brian A. Markison
President and Chief Executive Officer
POWER OF ATTORNEY
KNOW ALL MEN BY THESE PRESENTS that the undersigned officers and directors of King
Pharmaceuticals, Inc., a Tennessee corporation, hereby constitute and appoint Brian A. Markison the
true and lawful agent and attorney-in-fact, with all power of substitution and resubstitution, to
sign for the undersigned, in their respective names as officers and directors of the corporation,
one or more registration statements on Form S-8 (or other appropriate form) to be filed with the
Securities and Exchange Commission, Washington, D.C., under the Securities Act of 1933, as amended,
and any amendment or supplement to such registration statement, relating to the King
Pharmaceuticals, Inc. Executive Deferred Compensation Plan; hereby ratifying and confirming all
acts taken by such agent and attorney-in-fact as herein authorized.
Pursuant to the requirements of the Securities Act of 1933, as amended, this registration
statement has been signed by the following persons in the capacities
indicated and as of July 22, 2005.
Signature
Title
/s/ Brian A. Markison
President, Chief Executive Officer and Director (principal
executive officer)
Brian A. Markison
/s/ Joseph Squicciarino
Joseph Squicciarino
Chief Financial Officer
(principal financial officer)
/s/ Ted G. Wood
Ted G. Wood
Chairman of the Board, Director
/s/ Earnest W. Deavenport, Jr.
Earnest W. Deavenport, Jr.
Director
/s/ Elizabeth M. Greetham
Elizabeth M. Greetham
Director
/s/ Gregory D. Jordan
Gregory D. Jordan
Director
/s/ R. Charles Moyer
R. Charles Moyer
Director
6
Table of Contents
Signature
Title
/s/ Philip M. Pfeffer
Philip M. Pfeffer
Director
/s/ D. Greg Rooker
D. Greg Rooker
Director
7